Delivery Order SPE2DB20D1109-SPE2DB25FP42H
- Not listed
- The Defense Logistics Agency awarded a $18,121.68 delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectable medication in 2 ml quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 14, 2025. The contract is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, and represents a child delivery order under the...
- The Defense Logistics Agency (DLA) awarded a $11,827.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform work at its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $48,006.54 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a $8,920.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen (2 ml) pharmaceutical supplies with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The place of performance...
- The Defense Logistics Agency awarded a $6,049.03 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens (2 mL units) with a firm fixed price structure and an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with the federal government. The order will be fulfilled from the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- This is a $3,304.72 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The order is for DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has a completion date of September 13, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts and Indefinite Delivery Contracts (IDCs) to supply a wide range of medical commodities, including...
- The Defense Logistics Agency awarded a $7,883.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of DUPIXENT 300 mg/2 mL pens (2 mL units). This contract is non-set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The point of performance is located in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order valued at $8,632.83 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2ML). The contract, executed on August 28, 2025, with completion targeted for August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through competitive procurement processes. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,523.82 to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injections on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP42HDelivery Order
The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies to military and veteran healthcare systems through its DLA contracts. DUPIXENT (dupilumab) is a specialty biologic medication used to treat various inflammatory conditions, and this delivery order represents one of numerous pharmaceutical commodity requisitions fulfilled by the company under its broad global pharmaceutical support vehicle. The contract demonstrates AmerisourceBergen's capability to meet federal procurement requirements through competitive award and its role as a critical vendor in the Defense Health Agency and broader military healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 7/18/25 |